Krystal Biotech (KRYS) EBT (2016 - 2026)

Krystal Biotech has reported EBT for 11 years, with the latest figure at $66.1 million in Q2 2026.

• EBT for Q2 2026 came in at $66.1 million, up 41.27% year-over-year; the trailing twelve-month figure through Jun 2026 was $226.6 million (up 34.29% YoY), and the FY2025 annual result was $189.5 million, up 98.7% from the prior year.
• EBT advanced to $66.1 million in Q2 2026, from $61.4 million in the prior quarter.
• Over five years, EBT peaked at $80.7 million in Q3 2023 and troughed at -$114.3 million in Q1 2023.
• A 5-year average of $6.4 million and a median of $22.9 million in 2024 frame the typical range for EBT.
• The widest annual swing landed in 2022, when EBT tumbled 106.66%; it then surged 4577.79% in 2025.
• A 5-year view of EBT shows it stood at -$34.0 million in 2022, then surged by 131.32% to $10.7 million in 2023, then surged by 356.13% to $48.6 million in 2024, then advanced by 5.19% to $51.1 million in 2025, then rose by 29.23% to $66.1 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $66.1 million in Q2 2026, $61.4 million in Q1 2026, and $51.1 million in Q4 2025.